Instrument: Electron Microscope, Model JEM–1011. *Manufacturer:* JEOL, Japan. *Intended Use: See* notice at 69 FR 34654, 2004. *Order Date:* December 16, 2003.

Docket Number: 04–012. *Applicant:* University of Los Angeles, Los Angeles, CA 90095–1547. *Instrument:* Dual Beam Electron Microscope/Focused Ion Beam Milling Machine, Model Nova 600 Nanolab. *Manufacturer:* Fei Company, the Netherlands. *Intended Use: See* notice at 69 FR 34654, June 22, 2004. *Order Date:* August 6, 2003.

Comments: None received. *Decision:* Approved. No instrument of equivalent scientific value to the foreign instrument, for such purposes as these instruments are intended to be used, was being manufactured in the United States at the time the instruments were ordered. *Reasons:* Each foreign instrument is a conventional transmission electron microscope (CTEM) and is intended for research or scientific educational uses requiring a CTEM. We know of no CTEM, or any other instrument suited to these purposes, which was being manufactured in the United States either at the time of order of each instrument OR at the time of receipt of application by U.S. Customs and Border Protection.

Gerald A. Zerdy,

Program Manager, Statutory Import Programs Staff.

[FR Doc. 04–16129 Filed 7–15–04; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

Cornell University; Notice of Consolidated Decision on Applications for Duty-Free Entry of Scientific Instruments

This is a decision consolidated pursuant to section 6(c) of the Educational, Scientific, and Cultural Materials Importation Act of 1966 (Pub. L. 89–651, 80 Stat. 897; 15 CFR part 301). Related records can be viewed between 8:30 a.m. and 5 p.m. in Suite 4100W, Franklin Court Building, U.S. Department of Commerce, 1099 14th Street, NW., Washington, DC.

Comments: None received. *Decision:* Approved. No instrument of equivalent scientific value to the foreign instruments described below, for such purposes as each is intended to be used, is being manufactured in the United States.

Docket Number: 04–010. *Applicant:* Cornell University, Ithaca, NY 14853. Instrument: X-ray Double Crystal Monochrometer. *Manufacturer:* Kohzu Precision Co.,Ltd., Japan. *Intended Use: See* notice at 96 FR 34654, June 22, 2004. *Reasons:* The foreign instrument provides immediate accommodation into the facility's existing crystal mounting system without any degradation in ultimate performance. Any domestic equivalent would require extensive design and might not guarantee performance. Advice received from: The National Institutes of Health, June 28, 2004.

Docket Number: 04–013 *Applicant:* Cornell University, Ithaca, NY 14853. *Instrument:* X-ray Mirror Focusing System, Model Ne Cat. *Manufacturer:* Oxford-Danfysik, United Kingdom. *Intended Use: See* notice at 69 FR 34654, June 22, 2004. *Reasons:* The foreign instrument provides that both the horizontal and the vertical focusing mirrors can be located in the same vacuum vessel. This is required to provide adequate focusing and bending of the X-ray beam. *Advice received from:* The National Institutes of Health, June 28, 2004.

The capabilities of each of the foreign instruments described above are pertinent to each applicant's intended purpose and we know of no domestic instrument or apparatus of equivalent scientific value for the intended use of each instrument.

We know of no other instrument or apparatus being manufactured in the United States which is of equivalent scientific value to any of the foreign instruments.

Gerald A. Zerdy,

Program Manager, Statutory Import Programs Staff.

[FR Doc. 04–16128 Filed 7–15–04; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[Docket 040621190–4190–01]

Drug Pricing Study

AGENCY: International Trade Administration, Commerce.

ACTION: Notice of hearing.

SUMMARY: Information is sought related to a study of international drug pricing, mandated by Section 1123 of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the Act). This information will contribute to a report on trade in pharmaceuticals, focusing on the drug pricing practices of countries that are members of the Organization for Economic Cooperation and Development (OECD) (specifically Canada, Poland, France, Germany, United Kingdom, Japan, Switzerland, Greece, Australia, Korea, and Mexico) and the effects of those practices on drug pricing in the United States, research and development, and innovation. The Department is therefore holding a public hearing on August 3, 2004, and requesting written testimony in advance of the hearing.

DATES: Notification of intent to testify and written testimony should be submitted no later than 5 p.m. August 2, 2004. The hearing will be conducted on: August 3, 2004. For members of the public who are unable to attend the public hearing or who wish to submit rebuttal comments, ITA will accept comments from August 3 until August 13, 2004.

ADDRESSES: Schedule time for testimony and submit written testimony through Kristie Mikus: Department of Commerce, 14th and Constitution Avenue, Room 4053, Washington, DC 20230, e-mail *drugpricing@ita.doc.gov*; telephone (202) 482–0131; fax (202) 482–2565. The hearing will be conducted at: Department of Commerce, 14th and Constitution Avenue, Room 3407, Washington, DC 20230, on August 3, 2004.

FOR FURTHER INFORMATION CONTACT: For further information, please contact Kristie Mikus at (202) 482–0131 or at *drugpricing@ita.doc.gov.*

SUPPLEMENTARY INFORMATION: The International Trade Administration (ITA) publishes this notice of a public hearing to solicit information, as mandated by the Act. The hearing will take place on August 3, 2004 at 9 a.m. at the Department of Commerce, 14th and Constitution Avenue, Room 3407, Washington, DC, and will conclude at 5 p.m. or the close of business.

The Act directs the President's designees to conduct a study and report on issues related to trade and pharmaceuticals. Public Law 108–173, 117 Stat. 2066, 2469. Legislative history provides additional information concerning Congress' intent on the matter. Specifically, Conference Report 108–391 directs the Secretary of Commerce, in consultation with the International Trade Commission, the Secretary of Health and Human Services and the U.S. Trade Representative, to conduct a study and produce a report on trade in pharmaceuticals, focusing on the drug pricing practices of countries that are members of the OECD. Specifically, the Conference Report to the Act states:

''Report on Trade in Pharmaceuticals''

The Conference agreement directs the Secretary of Commerce, in consultation with the International Trade Commission, the Secretary of Health and Human Services and the United States Trade Representative, to conduct a study and report on drug pricing practices of countries that are members of the Organization for Economic Cooperation and Development and whether those practices utilize non-tariff barriers with respect to trade in pharmaceuticals. The study shall include an analysis of the use of price controls, reference pricing, and other actions that affect the market access of United States pharmaceutical products.

The study shall include the following:

Identification of the countries that use price controls or other such practices with respect to pharmaceutical trade.

Assessment of the price controls and other such practices used by the countries identified.

Estimate of additional costs to U.S. consumers because of such price controls and other such practices, and the extent to which additional costs would be reduced for U.S. consumers if price controls and other such practices are reduced or eliminated.

Estimate of the impact such price controls, intellectual property laws, and other such measures have on fair pricing, innovation, generic competition, and research and development in the United States and each country identified.''

ITA previously published a Request for Comments on June 1, 2004, **Federal Register**, Volume 69, Number 105, Page 30882–30883. The comment period for this request for comments closed on July 1, 2004. However, additional information is needed to complete the report for Congress. Consequently, the Department is seeking input to the following questions. However, in responding to these questions, please feel free to also include any relevant additional information or input. Individual testimony will be limited to 15 minutes. Because of the finite amount of time available during the public hearing, ITA may not be able to accommodate everyone who expresses an interest in testifying at the hearing. Therefore, ITA will provide an additional comment period between August 3 and August 13 to allow the public to submit comments on the questions below or in response to testimonies.

- How do OECD countries set pharmaceutical prices? Within OECD countries, what mechanisms do governments use to control pharmaceutical expenditures?
- If price controls and other government cost control mechanisms were eliminated in OECD countries, how and to what degree would pharmaceutical prices and expenditures change? What effects would these changes have on the sales and profits of pharmaceutical manufacturers?
- How do patent laws and their application affect prices of patented drugs in OECD countries?
- If price controls and other government cost control mechanisms were eliminated in OECD countries, what effect would there be on U.S. consumers?
- What factors influence, and how do companies determine research and development (R&D) expenditures? How would R&D be affected by higher prices and revenues from sales in OECD countries?
- What is the relationship between increased R&D by pharmaceutical manufacturers and the introduction of new drugs?
- Could OECD countries reduce costs by increasing the use of generic drugs? What steps would the governments need to take to facilitate the use of generic drugs?
- Are there means by which OECD countries could improve incentives for developing innovative medicines without significantly increasing spending on drugs?

Once completed, the report produced by ITA will be submitted to Congress and made available to the public.

Dated: July 13, 2004.

Douglas B. Baker,

Deputy Assistant Secretary for Service Industries, Tourism and Finance for the Office of the Assistant Secretary for Trade Development.

[FR Doc. 04–16219 Filed 7–15–04; 8:45 am]

BILLING CODE 3510–25–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Evaluation of Coastal Zone Management Programs and National Estuarine Research Reserves

AGENCY: Office of Ocean and Coastal Resource Management, National Ocean Service, National Oceanic and Atmospheric Administration (NOAA), DOC.

ACTION: Notice of intent to evaluate.

SUMMARY: The NOAA Office of Ocean and Coastal Resource Management (OCRM) announces its intent to evaluate the performance of the Hawaii Coastal Management Program; the Narragansett Bay National Estuarine Research Reserve, Rhode Island; the Minnesota Coastal Management Program; the Hudson River National Estuarine Research Reserve, New York; and the Washington Coastal Management Program and Padilla Bay National Estuarine Research Reserve, Washington.

The Coastal Zone Management Program evaluations will be conducted pursuant to section 312 of the Coastal Zone Management Act of 1972 (CZMA), as amended, and regulations at 15 CFR Part 923, Subpart L. The National Estuarine Research Reserve evaluations will be conducted pursuant to sections 312 and 315 of the CZMA and regulations at 15 CFR Part 921, Subpart E and Part 923, Subpart L.

The CZMA requires continuing review of the performance of states with respect to coastal program implementation. Evaluation of Coastal Zone Management Programs and National Estuarine Research Reserves requires findings concerning the extent to which a state has met the national objectives, adhered to its Coastal Management Program document or Reserve final management plan approved by the Secretary of Commerce, and adhered to the terms of financial assistance awards funded under the CZMA.

The evaluations will include a site visit, consideration of public comments, and consultations with interested Federal, state, and local agencies and members of the public. Public meetings will be held as part of the site visits.

Notice is hereby given of the dates of the site visits for the listed evaluations, and the dates, local times, and locations of the public meetings during the site visits.

The Hawaii Coastal Management Program evaluation site visit will be held August 23–27, 2004. One public meeting will be held during the week. The public meeting will be on Monday, August 23, 2004, at 6 p.m., at St. Andrew's Priory School, Kennedy Hall, Room K111, 224 Queen Emma Square, Honolulu, Hawaii.

The Narragansett Bay National Estuarine Research Reserve, Rhode Island, evaluation site visit will be held September 14–17, 2004. One public meeting will be held during the week. The public meeting will be on Wednesday, September 15, 2004, at 12 noon at 55 South Reserve Drive, Prudence Island, Rhode Island.

The Minnesota Coastal Management Program evaluation site visit will be held September 27–October 1, 2004. Two public meetings will be held during the week. The first public meeting will be on Monday, September 27, 2004, at 7 p.m., in the Large